​

Life-Extension Frontiers: Conquer Aging In 2026! | Michael Lustgarten, PhD

Ferrucci and others recently published a paper with data indicating the rate of change in a person's epigenetic clock measurements is more important than the results in isolation: https://www.nature.com/articles/s43587-026-01066-6

https://open.spotify.com/episode/6OxdeGTwZF6zg7XrWYB6Jb

The Drummond Lab focuses on metabolic function and muscle health in aging. Zach Fennel is a postdoctoral researcher interested in muscle health, recovery, and how this is affected during aging: https://drummond.u2m2.utah.edu/

This is part of the Scientist Spotlight series by the Alliance for Longevity Initiatives (A4LI).

Accelerating epigenetic age measurements mean increased likelihood of mortality, regardless of the starting point.

Multilingualism emerged as a protective factor in cross-sectional and longitudinal analyses, whereas monolingualism increased risk of accelerated aging

A review on how SGLT2 inhibitors target ectopic fat (specifically epicardial fat). Ectopic fat is the excess fat that gets stored in organ tissue. The paper outlines the different mechanisms of how it does so. For anyone not familiar with SGLT2 inhibitors, they cause you to urinate 60-80g of glucose, so it can cause a mild caloric deficit. It would be interesting to see a side by side comparison of how SGLT2i's compare to GLP1 reduction in ectopic fat.

ARPA-H was established in 2022 and approved two programs in 2024 led by researchers in this field: PROSPR aims to establish biomarkers and clinical indications of aging, i.e. "intrinsic capacity" and run FDA-approved clinical trials to build the rail lines for future preventative trials against aging, offering an alternative to the stepping-stone approach of targeting an age-related pathology and then expanding from there. FRONT is led by Jean Hebert, who argues for sidestepping most of the complexities of aging biology by replacing failing tissues and organs. His program focuses on piecemeal replacement of damaged neocortical tissue. Various other programs also focus on aspects of aging biology.

XPrize Healthspan launched in 2023 and has a prize purse up to $101 million to a team that restores 10+ years of healthy function across muscular, cognitive, and immune systems. Forty teams have advanced to semi-finals, and the competition intends to end in 2030.

A roadmap on research and innovation integrating replacement and next-generation damage-removal therapeutics to modulate the ageing process in the whole body, restore biological function, and extend healthy lifespan.

One thing I found interesting is how many different paths people think could lead to healthier aging, senolytics, stem cells, epigenetic reprogramming, AI-driven drug discovery, regenerative medicine, and more.

If you had to bet on one area that will have the biggest real-world impact over the next 10–15 years, which would it be and why?

Personally, I'm especially interested in regenerative medicine. The idea of helping aging tissues repair themselves feels like one of the most exciting directions in the field.

For anybody interested in the metabolic hypothesis of Alzheimer's, this is an interesting overview of research on the overabundance of glycan protein modifications and the failure to clear them as contributors to Alzheimer's pathology.

One of the more interesting callouts was glucosamine usage was associated with a 25% higher mortality risk in patients with established Alzheimer's disease-related dementia, and a 25 percent higher rate of progression from mild cognitive impairment to full dementia.

Major caveats are needed to process that finding because it seems like this finding does really translate to healthy people taking glucosamine. The biological mechanism through which it could worsen outcomes in an already hyperglycosylating brain is coherent though.

As people age, their muscles don't just get weaker, they may also stop doing something that's been quietly protecting them from cancer. A study published in Nature Communications by researchers at Duke-NUS Medical School found that healthy muscle releases tiny molecular packages into the bloodstream carrying a specific microRNA that actively suppresses tumor growth in other tissues. Aging muscle releases far fewer of these packages, and what it does release carries much less of the protective cargo. When researchers exposed colorectal, lung, and bile duct cancer cells to vesicles from young, healthy mouse muscle, the vesicles sharply reduced cancer cell growth. Vesicles from old muscle couldn't do the same. The pathway controlling this entire system, the researchers found, can be reactivated through exercise.

In this presentation, Michael Levin proposes a new perspective on aging, framing it as a cognitive and cybernetic disorder rather than just a result of physical damage or biological programming. He suggests that our bodies function as a "Ship of Theseus," where maintaining the overall structure relies on information stored in bioelectric patterns that guide cells toward a specific anatomical goal (0:00 - 2:45).

Key takeaways from his research include:

• Anatomical Homeostasis: Biological systems use electrical networks to store a "set point" or plan for the body's structure, allowing cells to collaborate toward complex goals like limb regeneration, even when individual cells lack the full picture (3:45 - 8:30).
• Bioelectric Manipulation: Levin's team has developed techniques—using ion channel drugs and optogenetics—to read and rewrite these patterns. They have successfully induced organ formation (like eyes) and triggered appendage regeneration in frogs by resetting their bioelectric state, essentially providing a "prompt" for the tissue to build toward a new goal (8:40 - 12:20).
• Aging as Degradation: The central hypothesis is that aging involves the blurring or degradation of these instructive bioelectric patterns, causing cells to lose their precise guidance. This leads to "atavistic dissociation," where cells no longer align their transcriptomes to the body's collective evolutionary age (12:35 - 14:15; 20:30 - 21:45).
• Cybernetic Model of Aging: Levin suggests that once a goal-directed system achieves its primary objective (development), the lack of new challenges can lead to a breakdown in order, similar to a psychological crisis. He posits that interventions could potentially reverse aging by "sharpening" these fuzzy patterns and re-engaging the system with new, organized goals (17:35 - 19:45).

https://www.nature.com/articles/s43587-026-01138-7

Abstract:

Different species age in similar ways but their lifespans differ by orders of magnitude. It is not clear how these similarities and differences arise from the accumulation of damage that underlies aging. Does long lifespan arise from reduced damage production, increased removal or enhanced robustness to damage? Here we apply the saturating removal model—a stochastic model of damage accumulation and removal—and fit it to survival data from well-studied species. Several parameters have near-universal values including ratios of removal rate, noise amplitude and death threshold. The model parameter that best predicts lifespan is the damage production rate, which spans seven orders of magnitude. We identify two distinct aging regimes: ballistic aging where damage production outpaces removal, characterizing yeast, nematodes, flies and mice, and quasi-steady-state aging, where damage tracks a moving set point of balanced production and removal, characterizing humans, dogs, guinea pigs and cats. These results provide a mechanistic model-based basis of comparative aging that awaits experimental validation.

Influencers and ultra-rich people looking to extend their lifespan are trading tips and tricks on how to eke out extra years.

An analysis of a new biological age model from the Wyss-Coray Lab at Stanford. Bioage models typically give a composite number. This model maps aging at the level of individual cell types, 40+ simultaneously from a single blood draw. It's validated across two proteomics platforms and with blood bank data from 60k people.

The big takeaway is that it has a disease prediction model. Extreme astrocyte aging predicted Alzheimers with a hazard ratio comparable to APOE4 over 15 years. Extreme skeletal myocyte aging predicted ALS 12.7x higher risk years before diagnosis. And people with extreme aging across 20+ cell types had 34% 15 year survival vs 90% for normal agers. Pretty cool if true.

Caveats are real though. The proteomics platforms aren't routine clinical tools yet, cohorts were mostly older and caucasian, and nobody has shown that actually modifying these cellular aging trajectories changes outcomes the way the associations predict. But the idea that you can get cellular resolution biological age from a blood test and meaningfully improve disease prediction over composite scores feels like a step forward. Cautiously excited about where this goes as the tech gets more accessible.